Patents by Inventor Pu Hyeon Cha

Pu Hyeon Cha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11219656
    Abstract: The invention relates to a composition containing extracts of the fruit of Hovenia dulcis Thunb., gallocatechin, and methyl vanillate as active ingredients for preventing and treating bone disease. The extracts of the fruit of Hovenia dulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention are natural materials and thus cause no side effects, and may activate the Wnt/?-catenin pathway to promote bone formation rather than inhibiting bone decomposition, and therefore may be effective in treating osteoporosis and related diseases. In addition, the extracts of the fruit of Hovenia dulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention may have the effects regrowing hair and preventing and treating wounds and metabolic diseases related to the activation of Wnt/?-catenin pathway.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: January 11, 2022
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Kang Yell Choi, Pu Hyeon Cha
  • Publication number: 20180360901
    Abstract: The invention relates to a composition containing extracts of the fruit of Hovenia dulcis Thunb., gallocatechin, and methyl vanillate as active ingredients for preventing and treating bone disease. The extracts of the fruit of Hovenia dulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention are natural materials and thus cause no side effects, and may activate the Wnt/?-catenin pathway to promote bone formation rather than inhibiting bone decomposition, and therefore may be effective in treating osteoporosis and related diseases. In addition, the extracts of the fruit of Hovenia dulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention may have the effects regrowing hair and preventing and treating wounds and metabolic diseases related to the activation of Wnt/?-catenin pathway.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 20, 2018
    Inventors: Kang Yell Choi, Pu Hyeon Cha
  • Publication number: 20160038555
    Abstract: The invention relates to a composition containing extracts of the fruit of Hoveniadulcis Thunb., gallocatechin, and methyl vanillate as active ingredients for preventing and treating bone disease. The extracts of the fruit of Hoveniadulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention are natural materials and thus cause no side effects, and may activate the Wnt/?-catenin pathway to promote bone formation rather than inhibiting bone decomposition, and therefore may be effective in treating osteoporosis and related diseases. In addition, the extracts of the fruit of Hoveniadulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention may have the effects regrowing hair and preventing and treating wounds and metabolic diseases related to the activation of Wnt/?-catenin pathway.
    Type: Application
    Filed: March 30, 2012
    Publication date: February 11, 2016
    Inventors: Kang Yell Choi, Pu Hyeon Cha
  • Publication number: 20120034235
    Abstract: A composition for detecting a marker for the diagnosis or prognosis of liver cancer is disclosed. The composition includes an agent capable of assessing the expression level of UQCRH (ubiquinol-cytochrome c reductase hinge protein). In addition, a kit having the composition, a microarray for the diagnosis of liver cancer using the marker, and a method for detecting the marker, and predicting recurrence following surgery in liver cancer patients are disclosed. The marker is able to contribute to the early diagnosis of liver cancer and prediction of recurrence following surgery and survival of liver cancer patients who have undergone hepatic resection, and also is significant for being a promising therapeutic target for liver cancer.
    Type: Application
    Filed: January 22, 2010
    Publication date: February 9, 2012
    Applicant: KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES
    Inventors: Kee Ho Lee, Eun Ran Park, Pu Hyeon Cha, Sang Bum Kim, Sun Hoo Park, Dong Hyoung Lee, Seon Rang Woo, Chul Ju Han, Yong Ho Ham, Eun Ju Lee, Myoung Jin Park, Sang Gu Hwang, Hyun Jin Shin